LETTER TO THE EDITOR

Open Access

The Human Genome Organisation (HUGO) and the 2020 COVID-19 pandemic

Benjamin Capps 1*, Yann Joly 2, John Mulvihill 3, Won Bok Lee 4 and HUGO Committee on Ethics, Law and Society, and the HUGO Council

Abstract

This letter is the Human Genome Organisation’s summary reaction to the 2020 COVID-19 pandemic. It identifies key areas for genomics research, and areas in which genomic scientists can contribute to a global response to the pandemic. The letter has been reviewed and endorsed by the HUGO Committee on Ethics, Law and Society (CELS) and the HUGO Council.

Keywords: Human Genome Organisation, COVID-19, Genomics, Public health pathogen genomics

Letter to the Editor

It is over a year since the Program for Monitoring Emerging Diseases first detected the “urgent notice on the treatment of pneumonia of unknown cause” given by the Wuhan Municipal Health Committee. We now know the cause was Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is difficult to take stock, with projections suggesting the pandemic is far from over and knowing that the impacts on health and wellbeing, health systems, and economies will last for years. Many countries have experienced multiple sequential waves of infection; but even if we can only anticipate each wave being the last, a vaccine strategy and plans for an ethical rollout are at least on the horizon. Evidence-based treatments for very sick people are available, as long as the health system they are in has access to the treatments and capacity to provide care; and in countries where there has been effective leadership—responsive to ‘following the science’, promoting effective public health measures, and investing in effective testing—hospitalisations have often been manageable. In some places, through public health, community spread has been stopped. Across the globe, the pandemic has severely impacted national economies and the security of communities and households, but the social and economic inequality it has caused or exacerbated has not been shared by all [1, 2].

The first genetic sequence of the virus was transmitted to the WHO on 11th January 2020 and was immediately made available on the GISAID platform. That sequence was necessary for urgent diagnostics: the first step in combatting the virus’ spread in real time. Rigorous analyses of the viral genome, along with associated clinical data, has

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
improved knowledge of the disease and enhanced our clinical responses to it. The first vaccine licenced by a national body (in December 2020) uses a novel mRNA approach to express viral proteins to induce an adaptive immunological response. Gene editing will have a role in better, faster testing [4]2 and designer therapies [5]; and eventually, individual responses to treatments could be enhanced by pharmacogenomics [6]. Genomics has a role in predicting individual prognoses of COVID-19, but it is critically important to integrate social determinants of health into this equation.

We have also seen the rise of polemical ‘bad science’. With supremacists conspiring to use every opportunity to destabilise society for their own advantage, science has been misused to stoke eugenic and racist divisions, and isolate communities [7]. Public health responses to the pandemic have unfortunately highlighted class and racial divides in respect to health and economic priorities, which have been acutely felt by marginalised communities [8]. Politicisation has undermined public health [9]; such politicisation could hinder international cooperation, as it has done in previous zoonotic outbreaks [10]. Despite early promise of a global concord, nationalism of resources is inevitable [11]. It is in these respects, that the HUGO Council and HUGO Committee on Ethics, Law and Society supports the American Society of Human Genetics’ denouncement of the use of genetics to promote populism, supremacy, and ‘bad science’ [12, 13]. We share their view that all knowledge must be used to “advance science, improve health, and benefit people everywhere”.

In respect to genomics, we have three comments:

First, sharing sequences on open platforms has enabled a global pandemic strategy allowing for rapid dissemination of data, while also being an opportunity for enhanced scrutiny and detection of its flaws [14, 15]. There are ethical pitfalls in some Open Science models, especially those in which capitalist platforms (e.g. Amazon, Apple, Google, and Facebook, as well as data analysis start-ups such as Palantir and Clearview AI) provide essential public health activities based on neoliberal goals, rather than for the public good [16]. Researchers should be cautious with respect to who they collaborate with and consider the ethical as well as scientific implications of their decisions to publish preprints, and the timing and place of publication [17]. Too quick, or careless dissemination, allows errors to propagate before they are detected by traditional review processes; and in these cases, responsible researchers must be just as quick to correct them [18]. HUGO must help align resources to strengthen ‘precision public health pathogen genomics’ through its committees and annual conference; as such, it may frame the open commons for sharing and collaboration in a way that progresses science and supports our responses to genomic vulnerabilities [19]. We should also look forward to the time when the pandemic has passed, and we are left with vast amounts of samples and data: these should be made available under conditions of global ethics and a model that advances genomics research equitably.

Second, there continues to be limited effective integration of environmental factors in public health pathogen genomics. COVID-19 is a novel zoonotic disease, and, like other emergent infectious pathogens originating in wild animals, we poorly anticipate their pandemic potential. The detection of variants of the virus in farmed animals during the pandemic highlights a link between human and animal health [20]. Yet, despite initiatives to strengthen pathogen surveillance, disconnects remain between researchers, public health agencies, and policymakers in environmental matters. These silos undermine progress in sustaining healthy ecoservices, particularly in circumstances where human activities are known to cause zoonotic spillover [21]. Genomic sciences must also be integrated in all aspects of pandemic response, including building an innovative infrastructure for future comparative studies [22], as well as contributing to understanding the impact of COVID-19 on non-human animals [23].

Third, the ‘right to science’ strengthens bona fide discovery; therefore, HUGO could provide leadership in responding to scientific activities that prospectively obstruct or reduce social opportunities or capture of public resources. The pandemic—or ‘syndemic’—has shown how multiple biological and social interactions increase a person’s susceptibility to harm or worsen their health outcomes’ [24]. A key factor of our emergence from the pandemic will be how to create and sustain global equity, but we have already seen how public health measures can generate social disparities, and urgent access to cutting edge care will be a privilege many will not be afforded. Already, cracks in future effective and fair access to drugs and vaccines are showing because of political opportunism. HUGO reasserts that ‘genomic solidarity’ entitles everyone to access the benefits of research, so that citizens and scientists are joint owners in discovery and therefore must share its opportunities [25].

As we endure the present pandemic together, many face additional social and economic challenges, and it is
this that compelled members of HUGO to write this open letter. HUGO recognises the human genome is the common heritage of humanity, and therefore this pandemic should also be an opportunity to use it to support a global and collective response, inclusive of all nations and communities.

Acknowledgements
None.

Authors’ contributions
BC conceived of the letter and was lead author. YJ, WBL, and JM made contributions during its drafting. The HUGO Committee on Ethics, Law and Society (CELS), and the HUGO Council reviewed the letter, provided comments, and endorsed the content. The authors read and approved the final manuscript.

Authors’ information
BC is the chair of the HUGO CELS. YJ, WBL, and JM are members of CELS. Details of the CELS and HUGO Council, and their members, can be found at: http://www.hugo-international.org/

Funding
No sources of funding are declared.

Availability of data and materials
No sources of funding are declared.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Bioethics, Dalhousie University, 5849 University Avenue, CRC Building, Room C-312, PO Box 15000, Halifax, Nova Scotia B3H 4B2, Canada.
2McGill University, Montreal, Canada.
3University of Oklahoma Health Sciences Center, Oklahoma City, USA.
4Ewha Womans University, Seoul, South Korea.

Received: 30 December 2020 Accepted: 28 January 2021
Published online: 10 February 2021

References
1. Seshaiyer P, McNeely C. Challenges and opportunities from COVID-19 for global sustainable development. World Med Health Policy. 2020;12:443–53.
2. OECD. The Territorial Impacts of COVID-19 Managing the Crisis Across Levels of Government. 2020. oecd.org/coronavirus/policy-responses/the-territorial-impact-of-covid-19-managing-the-crisis-across-levels-of-government-d3e314e1/#section-d1e2545.
3. Atehortua N, Patino S. COVID-19, A tale of two pandemics: novel coronavirus and fake news messaging. Health Promot Int. 2021;36(1):237–47.
4. Broughton J, Deng Y, Yu G, et al. CRISPR-Cas12-based Detection of SARS-CoV-2. Nat Biotechnol. 2020;38:870–4.
5. Abbott T, Dhandhure G, Liu Y, et al. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Cell. 2020;181:865–76.
6. Takahashi T, Luzum J, Nicol M, et al. Pharmacogenomics of COVID-19 Therapies. NPJ Genom Med. 2020;5:35.
7. Nelson A. Weapons for when bigotry claims science as its ally. Nature. 2020;585:182–3.
8. Public Health Ontario. COVID-19 – What We Know So Far About Social Determinants of Health. May. 2020. Available at: https://www.publichealthontario.ca/-/media/documents/ncoy/covid-wwksf/2020/05/what-we-know-social-determinants-health.pdf?la=en.
9. Kamaran A. Covid-19, politisation, “corruption,” and suppression of science. BMJ. 2020;371:m4425.
10. Versluis E, van Asselt M, Kim J. The multilevel regulation of complex policy problems: uncertainty and the swine flu pandemic. Eur Policy Anal. 2019;5:80–98.
11. Faige E. Vaccine Nationalism Put World on Brink of ‘Catastrophic Moral Failure’. WHO Chief. Reuters. 2021; January 18. Available at: https://www.reuters.com/article/us-health-coronavirus-who/vaccine-nationalism-puts-world-on-brink-of-catastrophic-moral-failure-who-chief-idUSKBN29N078.
12. American Society of Human Genetics Statement Regarding Concepts of “Good Genes” and Human Genetics. 2020. September 24; https://www.ashg.org/publications-news/ashg-news/statement-regarding-good-genes-human-genetics/.
13. American Society of Human Genetics. ASHG denounces attempts to link genetics and racial supremacy. Am J Hum Genet. 2018;103:6366.
14. Editorial. COVID-19: a stress test for trust in science. Lancet. 2020;396:799.
15. Safieddine M, Kassir R. COVID 19 and the race to publish: an ethical issue. Br J Surg. 2020;107(11):e504.
16. Capps B. Where does open science lead us during a pandemic? A public good argument to prioritise rights in the open commons. Cambridge Q Healthc Ethics. 2021;30:11–4.
17. Pillier C, Servick K. Two elite medical journals retract coronavirus papers over data integrity questions. Science. 2020. Available at: https://www.sciencemag.org/news/2020/06/two-elite-medical-journals-retract-coronavirus-papers-over-data-integrity-questions.
18. Sparks J, Liew J, Putman M, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172:819–21.
19. Armstrong G, et al. Pathogen genomics in public health. N Engl J Med. 2019;381:2569–80.
20. Koopmans M. SARS-CoV-2 and the human-animal interface: outbreaks on mink farms. Lancet. 2021;21:P18–9.
21. Capps B, et al. Introducing one health to the ethical debate about zoonotic diseases in South East Asia. Bioethics. 2015;29:588–96.
22. Holmes E, Rambaut A, Anderson K. Pandemic: spend on surveillance, not politics. BMJ. 2020;371:m4425.
23. De Briyne N, et al. Overcoming the impact of COVID-19 on animal welfare: COVID-19 Thematic Platform on Animal Welfare. OEBulletin. 2020, October. Available at: https://oebulletin.com/?p=15661.
24. Horton R. COVID-19 is not a pandemic. Lancet. 2020;396:874.
25. Mulvihill J, et al. Ethical issues of CRISPR technology and gene editing through the lens of solidarity. Br Med Bull. 2017;122:17–29.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.